News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
Clinical - Phase II
Stemline Therapeutics, Inc. (STML) Announces SL-701 Granted Orphan Drug Designation For The Treatment Of Glioma 1/30/2015
Nuvo Research Inc. (NRI.TO) Reports Topline Results Of Phase 2 Study Of WF10™ For The Treatment Of Allergic Rhinitis 1/30/2015
Xencor Reports Top-line XmAb®5871 Phase 1b/2a Results Showing Promising Clinical Activity In Rheumatoid Arthritis 1/29/2015
Vericel Completes Patient Enrollment In Phase 2b ixCELL-DCM Clinical Study Of Ixmyelocel-T 1/29/2015
FDA Grants Orphan Drug Designations To OncoMed Pharmaceuticals, Inc. (OMED)'s Tarextumab For The Treatment Of Pancreatic And Small Cell Lung Cancer 1/29/2015
Provectus Biopharmaceuticals Inc. Begins Recruitment For Phase 2 Mechanism Of Action Clinical Trial Of PH-10 For Psoriasis 1/29/2015
Gynecologic Oncology Group Phase 2 Study Of Advaxis, Inc.'s Lm-LLO Immunotherapy, ADXS-HPV, For The Treatment Of Persistent Or Recurrent Cervical Cancer Achieves Safety And Efficacy Criteria 1/28/2015
Sorrento Therapeutics, Inc. Announces Completion Of Enrollment In The Cynviloq™ Registrational TRIBECA™ Study 1/28/2015
Biomay AG Reports Positive Phase 2b Data With The Innovative 3rd Generation Grass Pollen Allergy Vaccine BM32 1/28/2015
Aclaris Therapeutics Announces Positive Results From Phase 2b Clinical Trial Of A-101 For The Removal Of Seborrheic Keratosis, A Common Type Of Benign Skin Tumor 1/27/2015
Naurex Inc.'s First Orally Active Molecule, NRX-1074, Demonstrates Statistically Significant Improvement In Depression Scores Within 24 Hours In Phase 2 Study For Major Depressive Disorder 1/27/2015
Envisia Therapeutics Initiates Phase 2a Clinical Trial For ENV515 In Patients With Glaucoma 1/27/2015
Pivotal Therapeutics Inc. Receives Final Approval For Phase 2a Clinical Trial With PVT-100 1/27/2015
GlaxoSmithKline (GSK)'s Long-Awaited Ebola Vaccine Due to Arrive in Liberia 1/26/2015
Enlivex Therapeutics Ltd. Granted EU Orphan Drug Designation For Lead Product Apocell For Graft-Versus-Host Disease 1/26/2015
Shire (SHPGY)'s Investigational SHP609, idursulfase-IT, Receives FDA Fast Track Designation For The Treatment Of Neurocognitive Decline Associated With Hunter Syndrome 1/26/2015
Biocryst Pharmaceuticals (BCRX) Release: FDA Grants Fast Track Designation For BCX4161 For The Treatment Of Hereditary Angioedema 1/26/2015
Synageva BioPharma (GEVA) Announces Dosing Of Patients Commenced With SBC-103 In Phase 1/2 Study For Mucopolysaccharidosis IIIB And FDA Fast Track Designation Granted 1/26/2015
Opsona Therapeutics Ltd. Initiates A Prospective Open Label Phase 1/2 Study In Second-Line Lower (Low And Intermediate-1) Risk Myelodysplastic Syndrome (MDS) With OPN-305, A First-In Class Monoclonal Antibody That Blocks Toll-Like Receptor 2 1/26/2015
Genticel To Continue Per Protocol Its Phase 2 Clinical Study With Procervix After 2nd Review By The DSMB 1/26/2015
Progenics Pharmaceuticals, Inc. (PGNX) Relaunches Pivotal Trial Of AZEDRA™ In Pheochromocytoma 1/23/2015
Gem Pharmaceuticals Announces Enrollment Of Initial Patients In Its Phase 2 Clinical Trial To Assess The Efficacy And Safety Of GPX-150 In Sarcoma Patients 1/23/2015
CytRx Corporation (CYTR) Announces Overall Survival Results From Its Global Phase 2b Clinical Trial Of Aldoxorubicin In Soft Tissue Sarcoma 1/22/2015
Alexza Pharmaceuticals, Inc. (ALXA) Initiates Phase 2a Study Of AZ-002 (Staccato® alprazolam) In Epilepsy Patients 1/22/2015
Medivation, Inc. (MDVN) Release: Enzalutamide Phase 2 Terrain Trial Demonstrated Statistically Significant Increase In PFS As Compared To Bicalutamide In Metastatic Prostate Cancer 1/22/2015
Ocular Therapeutix, Inc. (OCUL) Enrolls First Patient In Phase 2 Clinical Trial For Sustained Release Dexamethasone For The Treatment Of Dry Eye Disease 1/21/2015
PharmaEngine, Inc. Announces Phase 2 PEPCOL Study Presented At The 2015 American Society of Clinical Oncology GI Of PEP02 (MM-398) In Combination With 5-FU/LV In Unresectable Metastatic Colorectal Cancer 1/21/2015
BioMarin (BMRN), Sarepta (SRPT) Rivalry Gets Nasty in Battle Over Data 1/21/2015
Spark Therapeutics Initiates Phase 1/2 Clinical Trial Of SPK-CHM For Choroideremia, Expanding Its Pipeline Of Potential Treatments For Rare, Blinding Conditions 1/20/2015
TauRx Therapeutics Release: First Evidence Of Potential Efficacy Of Tau Aggregation Inhibitor Therapy In Alzheimer's Disease 1/20/2015
Aduro Biotech Reports Long-Term Survival And Immune Biomarker Data From Phase 2 Clinical Trial Of Its Immuno-Oncology Regimen In Patients With Pancreatic Cancer 1/20/2015
AM-Pharma Starts Adaptive Phase 2 Trial Of Recap In Acute Kidney Injury 1/20/2015
BioInvent (BOVNF)’s Bi-1206 Antibody To Enter Collaborative Phase 1/2 Trial Funded And Conducted By Cancer Research UK, CRT And LLR 1/20/2015
Invion Limited Shows Off Positive Phase 2 Data for Smokers Trying to Quit 1/19/2015
Neurocrine Biosciences, Inc. (NBIX) Announces Granting Of Orphan Drug Status For NBI-77860 In Congenital Adrenal Hyperplasia 1/19/2015
Bone Therapeutics Demonstrates Efficacy In First Patient Cohort In ALLOB® Phase I/IIA Delayed-Union Trial 1/19/2015
J.P. Morgan: Juno Therapeutics (JUNO) Touts 10 New Drugs for Six Diseases, Loves New CAR-T Platform 1/16/2015
Amgen (AMGN) Presents New Data Supporting First-Line Use Of Vectibix® (Panitumumab) In Combination With FOLFOX In Patients With Wild-Type RAS Metastatic Colorectal Cancer 1/16/2015
Immodulon Therapeutics Ltd Release: In IMAGE 1, A Randomised Controlled Phase 2 Clinical Trial, Administration Of IMM-101 With Gemcitabine Demonstrates Significant Survival Advantage Over Gemcitabine Alone 1/16/2015
GenSpera Announces Positive Phase 2 Data For Investigational Agent Mipsagargin 1/16/2015
Phase II Clinical Data Of Peregrine Pharmaceuticals, Inc. (PPHM)' Bavituximab In Combination With Sorafenib Presented At American Society of Clinical Oncology Gastrointestinal Cancers Symposium 1/16/2015
Newron Pharmaceuticals (NWRN) Initiates Phase 2 Study Of sNN0029 In Patients With Amyotrophic Lateral Sclerosis 1/16/2015
Mesoblast Limited (MSB.AX) Reports Positive 24 Month Results In Phase 2 Trial For Chronic Low Back Pain And Initiation Of Phase 3 Program At J.P. Morgan Healthcare Conference 1/15/2015
Amarantus BioSciences, Inc. Announces Positive Data From 140 Subject LP-002 Clinical Study Of Lympro Test® Confirming Statistically Significant Markers For Alzheimer's 1/15/2015
TONIX Pharmaceuticals, Inc. (TNXP) Commences Phase 2 Trial Of TNX-102 SL In Post-Traumatic Stress Disorder 1/15/2015
PharmaCyte Biotech's Pancreatic Cancer Treatment Named As Near-Term Approach To Rising Pancreatic Cancer Rates 1/15/2015
Biocryst Pharmaceuticals (BCRX) Receives Positive Opinion On European Orphan Drug Designation For BCX4161 For The Treatment Of Hereditary Angioedema 1/14/2015
Auris Medical AG (EARS) Achieves 50% Enrollment Milestone In Post-Acute Tinnitus Stratum Of TACTT3 Clinical Trial 1/14/2015
Bellerophon Therapeutics Completes Enrollment In PRESERVATION I, A Trial Of Bioabsorbable Cardiac Matrix (BCM) For The Prevention Of Congestive Heart Failure After A Heart Attack 1/14/2015
Newron Pharmaceuticals (NWRN) Initiates Phase 2 Study Of sNN0031 In Patients With Parkinson’s disease 1/14/2015
Celsus Therapeutics (CLTX) Completes Enrollment Of Phase 2 Trial Of MRX-6 Cream 2% In Pediatric Atopic Dermatitis 1/13/2015
Capricor Therapeutics, Inc. Initiates The DYNAMIC Clinical Trial For The Treatment Of Advanced Heart Failure 1/13/2015
Aduro Biotech Announces Phase 2 Clinical Trial Results For Pancreatic Cancer Combination Immunotherapy Published In Journal Of Clinical Oncology 1/13/2015
Relmada Therapeutics Reaches Midway Point In Dose Escalation For Phase One Study Of Novel NMDA Receptor Antagonist D-Methadone 1/13/2015
Precision Biologics Release: NPC-1C Therapy Provides Hope For Patients With Metastatic Colorectal Cancer Showing Exciting Preliminary Results 1/13/2015
Global Blood Therapeutics Announces First Cohort Dosed In Phase 1/2 Trial Of GBT440 In Sickle Cell Disease 1/13/2015
SAGE Therapeutics Initiates Phase 2a Trial Of SAGE-547 In Postpartum Depression 1/12/2015
Anavex Life Sciences Corp. (AVXL.OB) Doses First Alzheimer's Patient In Phase 2a Trial Of ANAVEX 2-73 And ANAVEX PLUS 1/12/2015
Lion Biotechnologies, Inc. CSO Laszlo Radvanyi Co-Authors Study In Clinical Cancer Research 1/12/2015
Celator Pharmaceuticals, Inc. Announces Publication Of Promising Phase 2 Data For CPX-351 In First Relapse Acute Myeloid Leukemia Patients 1/12/2015
Clementia Opens Clinical Trial Site In Europe For Phase 2 Study Of Palovarotene In Patients With Fibrodysplasia Ossificans Progressiva (FOP) 1/12/2015
Arena Pharmaceuticals, Inc. (ARNA) Initiates Phase 2 Clinical Trial Evaluating Ralinepag For Pulmonary Arterial Hypertension 1/12/2015
DelMar Pharmaceuticals Provides Update On VAL-083 Clinical Trial And Outlines Corporate Objectives For 2015 1/12/2015
Milestone Pharmaceuticals Receives FDA Clearance Of MSP-2017 Phase 2 IND 1/12/2015
TapImmune Inc. (TPIV) Release: Positive Phase 1 Immune Responses In All Evaluable Ovarian And Breast Cancer Patients Advances Vaccine To Phase 2 Clinical Trials 1/12/2015
Sorrento Therapeutics, Inc. Provides Status Update On The Cynviloq™ Registrational TRIBECA™ Study 1/12/2015
NovoCure Ltd. Announces The Completion Of Enrollment Of Its PANOVA Trial Of Tumor Treating Fields Plus Gemcitabine For Treatment Of Pancreatic Cancer 1/12/2015
FDA Approves Antria Phase 2 Stem Cell Clinical Trials 1/12/2015
Sarepta Therapeutics (SRPT) Reports Long-Term Outcomes Through 168 Weeks From Phase 2b Study Of Eteplirsen In Duchenne Muscular Dystrophy 1/12/2015
Arrowhead Research Corporation (ARWR) Provides Update On IND For ARC-520 Phase 2b Study 1/12/2015
Conatus Pharmaceuticals Inc. Announces Top-Line Results From ACLF And Organ Impairment Clinical Trials Of Emricasan 1/9/2015
SCYNEXIS, Inc. (SCYX) Receives FDA Fast Track Designation For Oral Formulation Of SCY-078 For The Treatment Of Patients With Invasive Fungal Infections 1/9/2015
Argos Therapeutics, Inc. (ARGS) Provides Update On Clinical Research For Investigational Fully Personalized Immunotherapy For The Treatment Of HIV 1/9/2015
Regen BioPharma Identifies Second Generation Gene Silencing Candidates For Blocking Cancer Stem Cell Gene Target 1/9/2015
InVivo Therapeutics Corporation (NVIV) Announces Reopening Of Enrollment For Ongoing Pilot Trial 1/9/2015
MerLion Pharmaceuticals Pte Ltd’s Finafloxacin Shows Positive Phase 2 Results In Complicated Urinary Tract Infections 1/9/2015
TRACON Pharmaceuticals, Inc. Announces Results From A Clinical Trial Of TRC105 In Patients With Hepatocellular Carcinoma To Be Presented At The American Society of Clinical Oncology 2015 Gastrointestinal Cancers Symposium 1/9/2015
Infinity Pharmaceuticals Inc. (INFI) to Stop Developing Rheumaid Arthritis Drug 1/9/2015
New Biogen Idec (BIIB) MS Drug May Reverse Eye Scarring 1/9/2015
MerLion Pharmaceuticals Pte Ltd’s Finafloxacin Shows Positive Phase 2 Results In Complicated Urinary Tract Infections 1/8/2015
BIND Therapeutics (BIND) Provides Clinical Update For BIND-014 And 2015 Strategic Overview 1/8/2015
Infinity Pharmaceuticals Inc. (INFI) Reports Topline Results From Phase 2 Study Of Duvelisib In Rheumatoid Arthritis 1/8/2015
Biogen Idec (BIIB) Reports Positive Top-Line Results From Phase 2 Anti-LINGO-1 Trial In People With Acute Optic Neuritis 1/8/2015
Alexion Pharmaceuticals Inc. (ALXN) Provides Update On Phase 2 Clinical Trial With Eculizumab In Antibody Mediated Rejection (AMR) In Living-Donor Kidney Transplant Recipients 1/8/2015
Bio Blast Provides Update On Clinical Trial Of Cabaletta™ For Occulopharyngeal Muscular Dystrophy (OPMD) 1/8/2015
First Patient Successfully Transplanted With Cryopreserved (Frozen) Nicord® In Gamida Cell Ltd.'s Ongoing Phase I/II Clinical Trial For Blood Cancers 1/8/2015
GW Pharmaceuticals (GWPH) Provides Update On Epidiolex® Program In Treatment Resistant Childhood Epilepsies 1/8/2015
CytRx Corporation (CYTR) Announces Positive Interim Phase 2 Aldoxorubicin Results As A Treatment For HIV-Related Kaposi's Sarcoma (KS) 1/8/2015
ViaCyte, Inc. (Formerly Known as Novocell, Inc.) Receives Clearance From Health Canada For Diabetes Clinical Trial 1/8/2015
Galapagos Starts Phase 2 Trial With GLPG1205 In Ulcerative Colitis Patients 1/8/2015
Pharming Group (PHGUF.PK) And Salix Pharmaceuticals, Ltd. (SLXP) Announce First Patient Treated In Clinical Study Of Ruconest® For Prophylaxis Of Hereditary Angioedema 1/8/2015
Genervon Announces ALS Compassionate Use Results 1/8/2015
FDA Grants Soligenix (SNGX) "Fast Track" Designation For SGX301 For The First-Line Treatment Of Cutaneous T-Cell Lymphoma 1/7/2015
KaloBios Pharmaceuticals, Inc. (KBIO) Reports Top-Line Data For Phase 2 Study Of KB001-A To Treat Pseudomonas Aeruginosa Lung Infections In Cystic Fibrosis Patients 1/7/2015
Herantis Pharma Has Initiated Phase 2 Study With Cis-UCA Eye Drops In Patients With Dry Eye Syndrome, Results Expected In Q3/2015 1/7/2015
Zafgen (ZFGN) Announces Positive Results From Phase 2 Clinical Trial Of Beloranib In Hypothalamic Injury Associated Obesity 1/7/2015
Mirati Therapeutics  (MRTX) Doses First Patient In Phase 2 Study Of Mocetinostat In Bladder Cancer Patients With Genetic Alterations Of CREBBP And EP300 1/7/2015
Benitec, Inc. (BLT.AX) Advances Hepatitis C Clinical Trial 1/7/2015
ProNAi Therapeutics, Inc. Initiates Phase 2 Trial Of PNT2258 In Patients With Relapsed Or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) 1/7/2015
Trevena, Inc. (TRVN) Initiates Second Phase 2b Study Of TRV130 For Acute Postoperative Pain 1/7/2015
Genocea Biosciences Completes Enrollment Early In Phase 2 Dose Optimization Trial Of GEN-003 For Treatment Of Genital Herpes 1/7/2015
Kadmon Corporation Initiates Phase 2 Clinical Trial Evaluating KD025 In Psoriasis 1/7/2015
Otic Pharma Announces Positive Results From A Phase 2 Trial Of Foamotic Externa, Once-A-Day, Single Antibiotic, Steroid Free Product For Acute Otitis Externa (AOE) 1/7/2015
Alkermes plc (ALKS) Announces Positive Results Of Phase 2 Clinical Trial Of ALKS 3831 In Schizophrenia 1/7/2015
CytRx Corporation (CYTR) Announces Positive Interim Phase 2 Aldoxorubicin Results In Glioblastoma Multiforme (Brain Cancer) 1/6/2015
Mast Therapeutics (MSTX) Provides Update On Epic Study Enrollment And 2015 Milestones 1/6/2015
Ultragenyx Pharmaceuticals (RARE) Initiates New Development Program Studying KRN23 For The Treatment Of Tumor-Induced Osteomalacia 1/6/2015
Tobira Therapeutics Inc.' Cenicriviroc Granted Fast Track Designation By The FDA For The Treatment Of Nonalcoholic Steatohepatitis (NASH) In Patients With Liver Fibrosis 1/6/2015
Clearside Biomedical Initiates Phase 2 Clinical Trial For The Treatment Of Macular Edema Associated With Non-Infectious Uveitis 1/6/2015
Akebia Therapeutics, Inc. (AKBA) Completes Enrollment In The Two Planned Cohorts Of Its Phase 2 Study Of AKB-6548 In Patients With Anemia Related To Chronic Kidney Disease Undergoing Dialysis 1/6/2015
Ariad Pharmaceuticals, Inc. (ARIA) Announces Phase 2 Dose-Ranging Trial Of Iclusig (Ponatinib) To Begin By Mid-2015 1/6/2015
Gamida Cell Ltd.'s NiCord® Receives FDA And European Medicines Agency Orphan Drug Designation 1/6/2015
Cellular Biomedicine Group (CBMG) Initiates Patient Recruitment For Cartilage Damage Stem Cell Therapy Clinical Research Study 1/6/2015
CytRx Corporation (CYTR)'s Brain Cancer Drug Shows Promise in Mid-Stage Study 1/6/2015
Versartis, Inc. (VSAR) Announces Positive 12 Month Data For VRS-317 from Ongoing Extension Study 1/5/2015
Lion Biotechnologies, Inc. Submits Investigational New Drug Application To Conduct Phase 2 Study In Metastatic Melanoma 1/5/2015
Immunomedics, Inc. (IMMU) Awarded Fast Track Designation By FDA For Sacituzumab Govitecan (IMMU-132) For Triple-Negative Breast Cancer Therapy 1/5/2015
University of California, Los Angeles (UCLA) Launches Phase 2 Pediatric Clinical Trial For The Treatment Of ADHD With NeuroSigma, Inc.'s eTNS System 1/5/2015
Conatus Pharmaceuticals Inc. To Report Top-Line Results From ACLF And Organ Impairment Clinical Trials Of Emricasan 1/5/2015
BrainStorm Cell Therapeutics Inc. Announces Final Analysis Of Phase 2a ALS Study Showing Nearly All Subjects Experienced Clinical Benefit From NurOwn™ 1/5/2015
ReVance Therapeutics, Inc. (RVNC) Announces Initiation Of BELMONT Phase 2 Active Comparator Trial Of Injectable RT002 1/5/2015
Cellceutix (CTIX) Releases Confidence Interval Statistics Showing Clinical Success Rates For Brilacidin In Treatment Of ABSSSI 1/5/2015
NeuroDerm Ltd. (NDRM) Shares Double as Parkinson's Drug Shows Promise in Phase 2 Study 1/2/2015
Aquinox Pharmaceuticals (AQXP) Initiates Patient Dosing In The Phase 2 Clinical Trial Of AQX-1125 In Atopic Dermatitis 12/31/2014
NephroGenex (NRX) Announces Positive Results For QT Study Of Pyridorin 12/31/2014
NeuroDerm Ltd. (NDRM) Announces Topline Results Of Phase 2a Pharmacokinetic Study Of ND0612H And ND0612L, Continuous, Subcutaneously Delivered Levodopa/Carbidopa For The Treatment Of Parkinson's Disease 12/31/2014
Repros Therapeutics Inc. (RPRX) Initiates Two Phase 2B Uterine Fibroid Studies 12/30/2014
Ignyta (RXDX) Receives Orphan Drug Designation And Rare Pediatric Disease Designation From FDA For Entrectinib For The Treatment Of Neuroblastoma 12/29/2014
Athersys, Inc. (ATHX) Finishes Enrollment Of Phase 2 Study Of Multistem® Cell Therapy For Ischemic Stroke 12/29/2014
Versartis, Inc. (VSAR) To Hold Conference Call To Discuss VRS-317 Clinical Update From Ongoing Extension Study 12/29/2014
RegeneRx Biopharmaceuticals, Inc. (RGRX) Partner Submits Phase 2B/3 IND To Korean Health Authority For RGN-259 For The Treatment Of Dry Eye Syndrome 12/29/2014
Five Quick Takes on Stem Cells: CIRM, Sanford-Burnham Medical, BioWorld, StemCells (STEM), Cellular Dynamics 12/24/2014
Biocryst Pharmaceuticals (BCRX) Receives Orphan Drug Designation For BCX4161 For The Treatment Of Hereditary Angioedema 12/24/2014
Achillion Pharmaceuticals, Inc. (ACHN) Surges as Potential Drug Combo Seen as Hepatitis C Cure 12/23/2014
NeuroLifeSciences Release: Redefining ADHD: A New Approach & A Shift Of Paradigm In ADHD Therapeutics 12/23/2014
Provectus Biopharmaceuticals Inc.’ Protocol For Phase 2 Study Of Mechanism Of Action Of PH-10 On Immunologic Makers Of Psoriasis Now Available Online 12/23/2014
BioTie Therapies Corp. Announces Start Of Syn120 Phase 2a Trial In Parkinson's Disease Dementia And Provides Outlook Update For Near Term Pipeline Events 12/23/2014
Cellceutix (CTIX) Reports Positive Results Of Brilacidin In Microbiological Intent-To-Treat Population In Phase 2b ABSSSI Trial; Additional Pharmacokinetic Information To Be Submitted 12/23/2014
Achillion Pharmaceuticals, Inc. (ACHN) Shows Potential For "Best-In-Disease" HCV Regimen - 100% SVR4 Following A Dual 6-Week ACH-3102-Based Regimen And Separately A 4.8 Log10 Reduction With ACH-3422 12/22/2014
VBL Therapeutics (VBLX) Announces Positive Phase 2a Data For VB-111 In Recurrent Thyroid Cancer 12/22/2014
FDA Grants Orphan Drug Designation To Nuvilex (NVLX) For Pancreatic Cancer Treatment 12/22/2014
Can-Fite BioPharma (CFBI) Doses First Patient In Global Phase 2 Liver Cancer Trial For CF102 12/22/2014
Eiger Bio Announces Positive Data In Patients Infected With Hepatitis Delta Virus (HDV) Treated With Lonafarnib - Results Presented At American Association for Study of Liver Diseases Meeting 12/22/2014
MEI Pharma (MEIP) (Formerly known as Marshall Edwards, Inc.) (MSHL) Reaches Response Milestone In Phase 2 Clinical Trial Of Pracinostat In Refractory Myelodysplastic Syndrome 12/22/2014
MediGene AG (MDGEF.PK) Receives Clinical Trial Approval For Phase I/II Study With DC Vaccine To Treat Acute Myeloid Leukaemia (AML) 12/22/2014
Cerus Corporation (CERS) Reports U.S. Phase 2 Clinical Trial Of INTERCEPT Red Blood Cells Met Primary Endpoint 12/22/2014
Second Phase Of GlaxoSmithKline (GSK)'s Ebola Vaccine Delayed 12/22/2014
Polaris Group Lead Therapeutic Candidate ADI-PEG 20 Receives Orphan Drug Designation In The United States And The European Union For The Treatment Of Malignant Pleural Mesothelioma 12/19/2014
AB Science (AB.PA): Report Of Positive Clinical Study Data In Metastatic Colorectal Cancer 12/19/2014
Innate Pharma (IPH.PA ): First Phase 2 Trial With IPH2201 Open In Head And Neck Cancer 12/19/2014
Amarantus BioSciences, Inc. Submits Orphan Drug Designation Application To U.S. FDA For Treatment Of Retinal Artery Occlusion With Product Candidate MANF 12/19/2014
OncoGenex Pharmaceuticals Inc. (OGXI) Announces Results From The Phase 2 Borealis-1 Trial Of Apatorsen In The Treatment Of Metastatic Bladder Cancer 12/19/2014
Halozyme Therapeutics, Inc. (HALO) Receives European Orphan Drug Designation For PEGylated Recombinant Human Hyaluronidase PH20 For Pancreatic Cancer 12/19/2014
Xenetic Biosciences Completes Enrollment Of Second Cohort In Phase 2a Study With Erepoxen® For Anemia; Hemoglobin Levels Rise Into Therapeutic Range Over Time 12/19/2014
TetraLogic Pharmaceuticals (TLOG) Announces Initiation Of A Randomized Phase 2 Clinical Trial Of SHAPE In Subjects With Cutaneous T-Cell Lymphoma 12/18/2014
Fate Therapeutics (FATE) Announces Interim Data From Ongoing Phase 2 PUMA Study 12/18/2014
Biocryst Pharmaceuticals (BCRX) Initiates Opus-2: A Clinical Trial Of BCX4161 In Patients With Hereditary Angioedema 12/18/2014
StemCells Inc. (STEM) Transplants First Participant In Phase 2 Clinical Trial In Cervical Spinal Cord Injury 12/18/2014
Nuvo Research Inc. (NRI.TO) Reports That All Patients Have Completed Phase 2 Study Of WF10 For The Treatment Of Allergic Rhinitis 12/18/2014
D-Pharm Ltd. Achieves Primary End-Point In Phase 2 Clinical Study Of THR-18 In Acute Stroke Patients Treated With tPA 12/18/2014
ViaCyte, Inc. (Formerly Known as Novocell, Inc.) Release: Study Further Validates Cell Therapy Approach To Reverse Type 1 Diabetes 12/18/2014
Ablynx (ABLYF) Opens Recruitment For First-In-Infant Phase 2a Study With Its Anti-Rsv Nanobody, ALX-0171 12/17/2014
Stemline Therapeutics, Inc. (STML) Initiates SL-401 Clinical Trial In Four Rare Myeloproliferative Neoplasms 12/17/2014
RXi Pharmaceuticals (RXII) Announces Sustained Effect Of RXI-109 At Three Months Post Scar Revision Surgery And The Completion Of Enrollment For Its Phase 2a Trial RXI-109-1301 12/17/2014
Pfizer (PFE) Initiates Phase 2 Study Of PF-06252616 In Duchenne Muscular Dystrophy 12/17/2014
Pivotal Therapeutics Inc. Release: VASCAZEN POMEGA Phase 2a Trial Protocol Cleared Clinical Evaluation By French FDA 12/17/2014
Velocity Pharmaceutical Development And Tigercat Pharma, Inc. Announce Phase 2 Results For VPD-737 In Patients With Chronic Pruritus 12/17/2014
First Patient Treated In Mapi Pharma's Phase 2a Clinical Trial Of GA Depot For Relapsing Remitting Multiple Sclerosis (RRMS) 12/17/2014
Poxel Announces Positive Top Line Results For Its Antidiabetic Agent Imeglimin In A Phase 2b Dose-Ranging Trial 12/17/2014
Neovacs SA Announces Top Line Phase 2b Clinical Trial Results Of TNF-Kinoid In Rheumatoid Arthritis And Update On Clinical Programs 12/16/2014
Anavex Life Sciences Corp. (AVXL.OB) Begins Enrollment Of Alzheimer's Patients In Phase 2a Clinical Trial Of ANAVEX 2-73 And ANAVEX PLUS 12/16/2014
Galapagos NV (GLPG.BR) Regains Full Rights To GPR84 Inhibitor GLPG1205 12/16/2014
GENFIT Corp. (ALGFT): Gft505 Treatment Prevents Evolution To Cirrhosis 12/16/2014
SOV Therapeutics Announces Successful Phase 2b Study Of Oral Testosterone Undecanoate For Treatment Of Primary And Secondary Hypogonadism In Adult Males 12/16/2014
Isis Pharmaceuticals, Inc. (ISIS) Initiates Phase 1/2 Study Of ISIS-DMPK Rx In Patients With Myotonic Dystrophy Type 1 12/16/2014
OncoGenex Pharmaceuticals Inc. (OGXI) Announces Completion Of Patient Enrollment In The Rainier™ Clinical Trial Evaluating Apatorsen In Combination With ABRAXANEв Plus Gemcitabine In Patients With Metastatic Pancreatic Cancer 12/16/2014
Bone Therapeutics Confirms Safety In ALLOB® Phase 1/2a Trial For Delayed-Union Fractures 12/16/2014
Why Gilead Sciences, Inc. (GILD) And AbbVie (ABBV) Are Keeping An Eye On Achillion Pharmaceuticals, Inc. (ACHN) 12/15/2014
VBL Therapeutics (VBLX) Announces Last Patient Out In Phase 2 Clinical Studies Of VB-201 In Psoriasis And Ulcerative Colitis 12/15/2014
Zafgen (ZFGN) Announces Initiation Of Phase 2b Trial Of Beloranib In Severe Obesity 12/15/2014
Araim Pharmaeuticals Release: New Study Published In Molecular Medicine Reports That Novel Agent Decreases Neuropathic Pain In Patients With Type 2 Diabetes 12/15/2014
Ascendis Pharma A/S Announces Positive Six-Month Interim Results From A Phase 2 Pediatric Study Of Once-Weekly Transcon Growth Hormone For The Treatment Of Growth Hormone Deficiency 12/15/2014
Can-Fite BioPharma (CFBI) Release: Second Part Of The Glaucoma Phase 2 Study Has Been Approved In A European Country 12/15/2014
Taiwan's TWi Biotech To Start Clinical Trial Of Gout Treatment 12/15/2014
Vaxil Publishes The Results Of Its Phase 1/2 Study Using Immucin In Myeloma Patients In The "British Journal Of Hematology" 12/15/2014
Astellas Pharma Inc. (ALPMY) Release: Data Presented From Phase 2 Study Of Enzalutamide In Advanced Androgen-Receptor Positive, Triple-Negative Breast Cancer 12/15/2014
ChemoCentryx, Inc. (CCXI) Announces Positive Results In Phase 2 Diabetic Nephropathy Trial With CCR2 Inhibitor CCX140 12/12/2014
ChemoCentryx, Inc. (CCXI)To Host Conference Call On Friday, December 12, 2014 To Discuss Top-Line Phase 2 Results In Patients With Diabetic Nephropathy With CCX140, An Orally Administered CCR2 Inhibitor 12/12/2014
TWi Pharmaceuticals, Inc. Receives Approval Of Protocol For Its Drug Ac-201 Controlled-Release Tablet, Phase 2 Clinical Trial In Both The United States And Taiwan 12/12/2014
Merck & Co. (MRK),NewLink Genetics Ebola Trial Suspended After Patients Complain Of Joint Pain 12/12/2014
Kamada Ltd. (KMDA) Announces Positive Interim Results From Phase 1/2 Clinical Study Of Its Human Alpha-1 Antitrypsin To Treat Graft-Versus-Host Disease Presented At American Society of Hematology Annual Meeting 12/11/2014
Karyopharm Therapeutics (KPTI) Initiates Third Registration-Directed Clinical Trial Of Oral Selinexor (KPT-330) 12/11/2014
International Breast Cancer Study Group, Breast International Group And Merck & Co. (MRK) Announce Opening Of International PANACEA Study Of Patients With HER2+ Breast Cancer 12/11/2014
Cellceutix (CTIX): Prurisol™ For Psoriasis -- FDA Agrees That Phase 2 Study May Begin 12/11/2014
Neurovance Announces Top-Line Study Results Suggest Lower Abuse Potential For Centanafadine Compared To Stimulants Used For Adult ADHD 12/11/2014
ARCA biopharma Announces Activation Of First Canadian Genetic-AF Clinical Trial Site 12/11/2014
FDA Grants BioMarin Pharmaceutical Inc. (BMRN) Orphan Drug Designation For NAGLU Fusion Protein, BMN 250, For The Treatment Of MPS IIIB (Sanfilippo Syndrome Type B) 12/10/2014
International Breast Cancer Study Group, Breast International Group And Merck & Co. (MRK) Announce Opening Of International PANACEA Study Of Patients With HER2+ Breast Cancer 12/10/2014
Naurex Inc.'s GLYX-13 Demonstrates Robust, Sustained Antidepressant Effects And Excellent Tolerability In Phase 2b Study 12/10/2014
Merck Announces Positive Data Investigating The Use Of Pembrolizumab In Patients With Advanced Triple-Negative Breast Cancer At 2014 San Antonio Breast Cancer Symposium 12/10/2014